Natalie Byrne - Researcher Profile | RDL Research Database

Publications

2 shown

Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Jonathan R. Dry , Sandra Pavey , Christine A. Pratilas +26 more

Abstract Selumetinib (AZD6244, ARRY-142886) is a selective, non–ATP-competitive inhibitor of mitogen-activated protein/extracellular signal–regulated kinase kinase (MEK)-1/2. Th...

2010 Cancer Research 259 citations

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares , Mikhail Dvorkin , Yuanbin Chen +97 more

2019 The Lancet 2014 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 2
Citations: 2,273
Institution: QIMR Berghofer Medical Research Institute

External Links

Google Scholar

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.